WuXi Biologics (Cayman) Inc., a company incorporated in the Cayman Islands, has announced the approval of a new grant of 64,117 restricted shares under its Restricted Share Award Scheme. The grant, approved by the Board on June 5, 2025, is subject to acceptance by the grantee. This decision aligns with the company's effort to allocate shares under the scheme, which currently has 187,681,267 restricted shares available for future grants. The Board, including independent non-executive directors, has deemed the grant as fair and reasonable, considering it beneficial for the interests of the company and its shareholders. The restricted shares are ordinary shares with a nominal value of US$1/120,000 each.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi Biologics (Cayman) Inc. published the original content used to generate this news brief on June 05, 2025, and is solely responsible for the information contained therein.